View Older Stories View More Recent Stories

Jan 2, 2025 08:00AM Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 13, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 15, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 12, 2024 07:00AM Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
Nov 4, 2024 08:00AM Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
Nov 1, 2024 08:00AM Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Oct 31, 2024 04:00PM Scholar Rock to Participate in Upcoming Investor Conferences
Oct 31, 2024 08:00AM Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting
Oct 18, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 7, 2024 07:00AM Scholar Rock (SRRK) Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy
Oct 7, 2024 07:00AM Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)
Sep 13, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 10, 2024 08:00AM Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
Sep 4, 2024 08:05AM Scholar Rock Holding (SRRK) Appoints Beth Shafer to Chief Business Officer
Sep 4, 2024 08:00AM Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
Aug 29, 2024 08:00AM Scholar Rock to Participate in Upcoming Investor Conferences
Aug 16, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2024 07:00AM Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
Jul 23, 2024 08:00AM Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Jul 12, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 24, 2024 07:01AM Scholar Rock Holding Corp. (SRRK): New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Jun 24, 2024 07:00AM Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Jun 18, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 3, 2024 04:00PM Scholar Rock (SRRK) Presents New Data from SRK-181 Phase 1 DRAGON Trial
Jun 3, 2024 04:00PM Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
May 28, 2024 08:00AM Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024 07:05AM Scholar Rock (SRRK) Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
May 22, 2024 07:00AM Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
May 20, 2024 08:00AM Scholar Rock to Participate in Upcoming Investor Conferences
May 17, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2024 08:00AM Scholar Rock to Host Investor Day on May 22, 2024
May 7, 2024 07:00AM Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
Apr 12, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 19, 2024 07:00AM Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
Mar 15, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2024 08:00AM Scholar Rock to Participate in Upcoming Investor Conferences
Feb 16, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15, 2024 08:00AM Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
Feb 6, 2024 08:00AM Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
Jan 25, 2024 08:00AM Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
Jan 23, 2024 08:02AM Scholar Rock (SRRK) Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
Jan 23, 2024 08:00AM Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
Jan 12, 2024 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2024 08:00AM Scholar Rock Provides Corporate Update and Highlights Priorities for 2024
Dec 19, 2023 08:00AM Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 15, 2023 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 17, 2023 04:15PM Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 7, 2023 07:15AM Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
Nov 3, 2023 04:01PM Scholar Rock (SRRK) Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients
Nov 3, 2023 04:00PM Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
View More Recent Stories View Older Stories